Charles Schwab Investment Management Inc. Trims Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Charles Schwab Investment Management Inc. reduced its ownership of Amphastar Pharmaceuticals by 6.1%, selling 21,286 shares, and now holds 326,226 shares worth approximately $9.46 million.
• Several institutional investors increased their stakes in Amphastar, with Signaturefd LLC boosting its holdings by 147.7% during the first quarter.
• Recent analyst reports have mixed views on the stock, with Wells Fargo and JPMorgan lowering their price targets, while Needham & Company upgraded the stock, indicating a consensus rating of "Moderate Buy."

Charles Schwab Investment Management Inc. trimmed its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 326,226 shares of the company's stock after selling 21,286 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Amphastar Pharmaceuticals worth $9,457,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AMPH. Signaturefd LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after buying an additional 520 shares in the last quarter. IFP Advisors Inc purchased a new position in Amphastar Pharmaceuticals during the 1st quarter valued at about $34,000. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $38,000. GAMMA Investing LLC grew its holdings in Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after purchasing an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

AMPH stock traded up $0.36 on Friday, hitting $30.62. The company had a trading volume of 290,905 shares, compared to its average volume of 571,141. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.39 and a 12-month high of $53.96. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 11.47 and a beta of 0.76. The stock's 50-day simple moving average is $24.48 and its 200 day simple moving average is $25.80.

Analysts Set New Price Targets

Several research firms recently weighed in on AMPH. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Bank of America boosted their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday. Wells Fargo & Company reduced their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.